Biogen | BIIB - Cost Of Sales

Stock Price
189.73
Daily Change
0.45 0.24%
Monthly
6.99%
Yearly
53.59%
Q2 Forecast
180.43

Biogen reported $797.5M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Amgen USD 1.6B 187M Mar/2026
Bayer EUR 4.5B 194M Dec/2025
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
Merck USD 2.94B 380M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Sanofi EUR 3.76B 344M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025